Cytos' candidate hypertension vaccine cuts morning BP in Phase IIa assessment

Switzerland-based Cytos Biotechnology AG says that data from a trial of a developmental hypertension vaccine, CYT006-AngQb, indicate that the agent conferred blood pressure reductions in patients with mild-to-moderate forms of the condition. The results suggest that the vaccine, which targets the vasoconstrictive angiotensin II protein, has application in controlling one of the major causes of the high blood pressure.

Cytos explained that CYT006-AngQb is designed to elicit an antibody response to the angiotensin II protein. The molecule, which forms part of the renin-angiotensin system, is important in blood pressure regulation, specifically because it causes blood vessels to constrict and thereby increases both circulatory systolic and diastolic pressures.

300mcg CYT006-AngQb cuts bp